DrugPatentWatch Database Preview
Details for Patent: 8,530,694
Which drugs does patent 8,530,694 protect, and when does it expire?
This patent has fifty-four patent family members in thirty-four countries.
Summary for Patent: 8,530,694
Title: | Proteasome inhibitors |
Abstract: | The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. |
Inventor(s): | Olhava; Edward J. (Newton, MA), Danca; Mihaela Diana (Mendham, NJ) |
Assignee: | Millennium Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 13/209,511 |
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,530,694
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Millennium Pharms | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-001 | Nov 20, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA | ➤ Sign Up | ||
Millennium Pharms | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-002 | Nov 20, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA | ➤ Sign Up | ||
Millennium Pharms | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-003 | Nov 20, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA | ➤ Sign Up | ||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,530,694
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
8,003,819 | Proteasome inhibitors | ➤ Sign Up |
8,772,536 | Proteasome inhibitors | ➤ Sign Up |
8,871,745 | Proteasome inhibitors | ➤ Sign Up |
7,442,830 | Proteasome inhibitors | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,530,694
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 067824 | ➤ Sign Up | |||
Australia | 2007357338 | ➤ Sign Up | |||
Brazil | PI0721905 | ➤ Sign Up | |||
Canada | 2695082 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |